(Q37762248)

22 August 2017

1 reference

title

Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection (English)

1 reference

22 August 2017

0 references

1

Caroline M Perry

1 reference

22 August 2017

publication date

1 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

volume

70

1 reference

22 August 2017

issue

9

1 reference

22 August 2017

page(s)

1189-1213

1 reference

https://scigraph.springernature.com/pub.10.2165/11203940-000000000-00000

22 August 2017

exact match

0 references

cites work

Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry

1 reference

12 December 2020

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

1 reference

12 December 2020

Maraviroc: perspectives for use in antiretroviral-naive HIV-1-infected patients

1 reference

12 December 2020

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

1 reference

12 December 2020

1 reference

12 December 2020

Novel targets for antiretroviral therapy: clinical progress to date

1 reference

12 December 2020

Discovery and development of small-molecule chemokine coreceptor CCR5 antagonists

1 reference

12 December 2020

Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists.

1 reference

12 December 2020

Maraviroc for treatment-naive patients with HIV-1 infection: is the glass half empty or half full?

1 reference

12 December 2020

Cerebrospinal fluid maraviroc concentrations in HIV-1 infected patients.

1 reference

12 December 2020

Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women

1 reference

12 December 2020

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection

1 reference

12 December 2020

Genotypic coreceptor analysis

1 reference

12 December 2020

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

1 reference

12 December 2020

Maraviroc for previously treated patients with R5 HIV-1 infection

1 reference

12 December 2020

Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients

1 reference

12 December 2020

The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers

1 reference

12 December 2020

A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.

1 reference

12 December 2020

British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

1 reference

12 December 2020

Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir

1 reference

12 December 2020

A new class of anti-HIV therapy and new challenges

1 reference

12 December 2020

Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers

1 reference

12 December 2020

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection

1 reference

12 December 2020

Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents

1 reference

12 December 2020

Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection.

1 reference

12 December 2020

A review of the clinical pharmacology of maraviroc. Introduction

1 reference

12 December 2020

The cost of antiretroviral drugs and influence on prescribing policies

1 reference

12 December 2020

Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists

1 reference

12 December 2020

The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development

1 reference

12 December 2020

Maraviroc: in vitro assessment of drug-drug interaction potential

1 reference

12 December 2020

Drug interactions with new and investigational antiretrovirals

1 reference

12 December 2020

Are the proposed env mutations actually associated with resistance to maraviroc?

1 reference

12 December 2020

A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals.

1 reference

12 December 2020

Assessment of the pharmacokinetics of co-administered maraviroc and raltegravir

1 reference

12 December 2020

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

1 reference

12 December 2020

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

1 reference

12 December 2020

10.2165/11203940-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

22 August 2017

1011423491

0 references

Fatcat ID

release_io5vnqt45bf47fa72qkwkochfe

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/io5vnqt45bf47fa72qkwkochfe

24 November 2022

mapped directly with Wikidata item

1 reference